New possibilities of pharmacotherapy for systemic lupus erythematosus: Prospects for the use of anifrolumab (monoclonal antibodies to type I interferon receptor)

Systemic lupus erythematosus (SLE) is a systemic autoimmune rheumatic disease of unknown etiology, characterized by overproduction of organ-specific autoantibodies to various components of the cell nucleus and the development of immune-inflammatory damage to internal organs. According to modern conc...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: E. L. Nasonov, A. S. Avdeeva, T. V. Popkova
Formatua: Artigo
Hizkuntza:Russo
Argitaratua: IMA-PRESS LLC 2021-10-01
Saila:Научно-практическая ревматология
Gaiak:
systemic lupus erythematosus
interferon
genetically engineered biological drugs
anifrolumab
Sarrera elektronikoa:https://rsp.mediar-press.net/rsp/article/view/3072
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak